Aerocrine files patent infringement suit against Medisoft in Germany

SOLNA, Sweden – 20 March 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced the filing with the District Court of Dusseldorf of a Complaint and Motion to prevent Medisoft, P.A.E from marketing and selling its exhaled Nitric Oxide (NO) analyser in Germany. The claim seeks both an injunction and damages.

Medisoft P.A.E. is a Belgian company that recently began marketing and selling the Hypair exhaled NO analyser in Germany. Aerocrine claims the Medisoft Hypair Analyser infringes four of Aerocrine's European patents. They are EP Nos. 0,606,351; 0,724,723; 1,439,781; and 1,545,305.

”Aerocrine´s view is that Medisoft’s product Hypair uses Aerocrine’s proprietary technology”, says Paul de Potocki, CEO of Aerocrine AB. “We welcome other companies to join Aerocrine in bringing the benefits of inflammation monitoring to patients and care providers, but we will defend our company’s patents resolutely”.

For more information, contact:

Paul de Potocki, CEO
Telephone: +46 8 629 07 82